GGrantIndex
← Leaderboards

Elizabeth G McFarland

University Of Colorado Denver

$39,720
Attributed
$39,720
Total exposure
10
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$39,720 · 10

By mechanism

M01$39,720 · 10

Top collaborators

No co-investigators on record.

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman Therapy EvaluationHuman SubjectDrug Screening /EvaluationHiv InfectionsPediatric AidsChild (0-11)Aids TherapyClinical Trial Phase IPharmacokineticsInfant Human (0-1 Year)Antiaids AgentHelper T LymphocyteCombination ChemotherapyPediatric PharmacologyProtease InhibitorAids VaccinesDosageVirus LoadNevirapineLamivudineMicroorganism Disease ChemotherapyChemopreventionDrug Tolerance

Grant awards (18)

ACTG 300--STUDY OF 3TC, ZDV AND DDI IN HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
ACTG 219--PEDIATRIC HIV LATE OUTCOMES PROTOCOL$0
M01 · FY2002 · RR
ACTG 326-- ALVAC HIV VACCINE IN CHILDREN BORN TO HIV INFECTED MOTHERS$0
M01 · FY2002 · RR
ACTG 345 PHASE I/II STUDY OF RITONAVIR IN HIV INFECTED INFANTS AND CHILDREN$0
M01 · FY2002 · RR
ACTG#316--NEVIRAPINE FOR PREVENTION OF MATERNAL-FETAL TRANS. OF HIV$0
M01 · FY2002 · RR
PHASE I/II TRIAL OF RECOMBINANT INTERLEUKIN 2 IN SYMPTOMATIC HIV INFECTED CHILD$0
M01 · FY2002 · RR
ACTG 254--ATOVAQUONE/AZITHROMYCIN VS TMP/SMX TO PREVENT BACTERIAL INFECTION$0
M01 · FY2002 · RR
ACTG 366-- NOVEL ANTIRETROVIRAL THERAPY IN ANTIRETROVIRAL EXP CHILD$0
M01 · FY2002 · RR
ACTG 230--SAFETY AND IMMUNOGENICITY OF HIV 1 ENVELOPE ANTIGEN CANDIDATE VACCINES$19,860
M01 · FY2000 · RR
ACTG 273: HIVIG IN SLOWING DISEASE PROGRESSION IN HIV INFECTED CHILD$19,860
M01 · FY2000 · RR
ACTG 366-- NOVEL ANTIRETROVIRAL THERAPY IN ANTIRETROVIRAL EXP CHILD$0
M01 · FY2000 · RR
ACTG 326-- ALVAC HIV VACCINE IN CHILDREN BORN TO HIV INFECTED MOTHERS$0
M01 · FY2000 · RR
ACTG 345 PHASE I/II STUDY OF RITONAVIR IN HIV INFECTED INFANTS AND CHILDREN$0
M01 · FY2000 · RR
ACTG#316--NEVIRAPINE FOR PREVENTION OF MATERNAL-FETAL TRANS. OF HIV$0
M01 · FY2000 · RR
PHASE I/II TRIAL OF RECOMBINANT INTERLEUKIN 2 IN SYMPTOMATIC HIV INFECTED CHILD$0
M01 · FY2000 · RR
ACTG 254--ATOVAQUONE/AZITHROMYCIN VS TMP/SMX TO PREVENT BACTERIAL INFECTION$0
M01 · FY2000 · RR
ACTG 300--STUDY OF 3TC, ZDV AND DDI IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 219--PEDIATRIC HIV LATE OUTCOMES PROTOCOL$0
M01 · FY2000 · RR